(Q49184612)

19 February 2018

title

CR represents an early index of potential long survival in multiple myeloma (English)

1 reference

19 February 2018

author name string

M Wang

1

1 reference

19 February 2018

K Delasalle

2

1 reference

19 February 2018

L Feng

3

1 reference

19 February 2018

S Thomas

4

1 reference

19 February 2018

S Giralt

5

1 reference

19 February 2018

M Qazilbash

6

1 reference

19 February 2018

B Handy

7

1 reference

19 February 2018

J J Lee

8

1 reference

19 February 2018

R Alexanian

9

1 reference

19 February 2018

language of work or name

English

0 references

publication date

27 July 2009

1 reference

19 February 2018

Bone Marrow Transplantation

published in

1 reference

19 February 2018

volume

45

1 reference

19 February 2018

issue

3

1 reference

19 February 2018

page(s)

498-504

1 reference

19 February 2018

Impact of additional cytoreduction following autologous SCT in multiple myeloma.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

International staging system for multiple myeloma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Analysis of survival by tumor response.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Evaluation of survival data and two new rank order statistics arising in its consideration

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

VAD-based regimens as primary treatment for multiple myeloma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Primary dexamethasone treatment of multiple myeloma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Single versus double autologous stem-cell transplantation for multiple myeloma.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5777472

Nonparametric Estimation from Incomplete Observations

14 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBMT.2009.176

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBMT.2009.176

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

21 January 2018

1 reference

12 December 2020

High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial

1 reference

12 December 2020

Relationship Between Depth of Response and Outcome in Multiple Myeloma

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Identifiers

DOI

10.1038/BMT.2009.176

1 reference

19 February 2018

Dimensions Publication ID

0 references

1 reference

19 February 2018

PubMed publication ID

19633690

1 reference

19 February 2018